0%
Print report
Variant interpretation report

MSH3 c.1327G>A, p.Ala443Thr

NM_002439.5:c.1327G>A NP_002430.3:p.(Ala443Thr) Missense · exon 8 View identifiers
Classification
Uncertain significance

Variant description:

The MSH3 NM_002439.5:c.1327G>A (NP_002430.3:p.(Ala443Thr)) missense variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About MSH3

MSH3 encodes a protein that partners with MSH2 to form MutS beta, a key component of the DNA mismatch repair system that recognizes and corrects errors made during DNA replication. It acts as a tumor suppressor: loss of MSH3 function leads to mismatch repair deficiency, an elevated mutation rate, and increased cancer risk, and the gene is frequently altered in mismatch repair-deficient colorectal cancers. Defects in MSH3 are linked to susceptibility to endometrial cancer, and inherited mutations are associated with an autosomal recessive form of familial adenomatous polyposis, with minimal evidence for a role in Lynch syndrome. Tumors with mismatch repair deficiency, including those involving MSH3, tend to respond well to immune checkpoint inhibitor therapies.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 1
Pathogenic criteria applied · 1
PM2Moderate
PM2 · moderate

Met at Moderate: gnomAD v4.1 total AF is 1.85893e-06, below the PM2 cutoff of 0.0001, with 0 homozygotes.

Benign criteria applied · 1
BP4Supporting
BP4 · supporting

Met: REVEL 0.222 is below the BP4 supporting cutoff of <=0.29 for this missense variant.

Recorded classification: Uncertain significance

VUS: PM2 (moderate) and BP4 (supporting) do not satisfy any generic ACMG/AMP pathogenic, likely pathogenic, benign, or likely benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
3 / 1,613,828 alleles

gnomAD v4.1: 3 / 1,613,828 alleles. Recorded AF 1.85893e-06. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.98096e-06; MAF= 0.00040%, 1/251196 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.80887e-06; MAF= 0.00088%, 1/113522 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.222 recorded score

Recorded REVEL score: 0.222. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
4 reported laboratory submissions

3 Uncertain significance · 1 Likely benign. ClinVar API review status: criteria provided, conflicting classifications.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. MSH3, a DNA mismatch repair protein, is frequently mutated in colorectal cancers.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 10 not met · 12 not assessed · 4 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

No VCEP covers MSH3, so generic ACMG/AMP 2015 definitions govern.

The exact variant is rare in gnomAD, but rarity alone is not case-control enrichment, phenotype specificity, alternate molecular basis, or an expert-panel PP5/BP6 assertion.

The exact-variant ClinVar record has no expert-panel submission; its single-submitter Likely benign assertion cannot trigger BP6 under the specified rule.

Generic ACMG/AMP rules govern because no VCEP covers MSH3.

This is a missense variant, so PP3 and BP4 were evaluated through the REVEL path only; the same REVEL score was not double-counted between criteria.

PP3 is not met and BP4 is met at Supporting strength based on REVEL 0.222.

Population evidence supports PM2 at Moderate strength because the variant is extremely rare in gnomAD, including the non-cancer exome subset, and no homozygotes are observed.

BA1, BS1, and BS2 are not met: the filtering frequency is far below benign-frequency thresholds and no healthy homozygote is reported.

Met · 2

PM2 ModerateACMG_2015Met at Moderate: gnomAD v4.1 total AF is 1.85893e-06, below the PM2 cutoff of 0.0001, with 0 homozygotes. Details ▾Hide ▴
Reasoning

PM2 is met at Moderate strength. The generic ACMG/AMP cutoff supplied for PM2 is <=0.0001. The variant is present at 1.85893e-06 in gnomAD v4.1 (3/1,613,828 alleles; 0 homozygotes), and at 4.22544e-06 in the gnomAD v2.1 non-cancer exome subset (1/236,662 alleles; 0 homozygotes). These frequencies are extremely low and below 0.0001, supporting PM2 for this recessive MSH3-associated condition; the ClinGen SVI downgrade to Supporting is not applied.

Rule
PM2: Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 reports AF=1.85893e-06, 3/1,613,828 alleles, and 0 homozygotes; its grpmax FAF is 6.8e-07.
  • gnomAD v2.1 non-cancer exomes report AF=4.22544e-06, 1/236,662 alleles, and 0 homozygotes.
  • Both observed frequencies are below the generic ACMG/AMP PM2 cutoff of 0.0001 (0.01%); PM2 is retained at the required Moderate 2015 strength.
Sources
BP4 SupportingACMGMet: REVEL 0.222 is below the BP4 supporting cutoff of <=0.29 for this missense variant. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_002439.5:c.1327G>A (p.Ala443Thr), so the generic missense path requires REVEL only. REVEL is 0.222, which is <= 0.29 and meets the generic BP4 supporting threshold; therefore BP4 is met at Supporting strength. SpliceAI (max delta 0.004) is not used for a missense BP4 assessment, and BayesDel is not available for generic ACMG/AMP strength calibration.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc) ... Missense variant -> REVEL only. ... BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Local REVEL lookup for MSH3 NM_002439.5:c.1327G>A (p.Ala443Thr): score 0.222.
  • ClinGen SVI REVEL calibration threshold supplied for generic BP4 supporting evidence: <= 0.29 (Pejaver et al. 2022, PMID:36413997).
  • The missense-specific rule selects REVEL only; the available SpliceAI max delta 0.004 and BayesDel score -0.384089 were not counted for BP4.
Sources
revel

Not met · 10 · evaluated, threshold not reached

PS1 ACMG_2015Not met: no previously established pathogenic MSH3 variant with the same p.Ala443Thr amino-acid change is documented. Details ▾Hide ▴
Reasoning

NM_002439.5:c.1327G>A is a missense variant, NP_002430.3:p.(Ala443Thr). The reviewed evidence contains no previously established pathogenic variant producing the same p.Ala443Thr amino-acid change through a different nucleotide change. ClinVar reports conflicting laboratory classifications with no expert-panel submission, so it does not establish a pathogenic same-amino-acid comparator for PS1.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Evidence considered
  • Variant identity: NM_002439.5:c.1327G>A, NP_002430.3:p.(Ala443Thr).
  • ClinVar variation 1055567 reports three uncertain-significance submissions and one likely-benign submission, with no expert-panel submission; this does not establish a pathogenic same-amino-acid comparator.
Sources
PS4 ACMG_2015Not met: no exact-variant affected-case/control comparison or OR >5.0 with a confidence interval excluding 1.0 was reported. Details ▾Hide ▴
Reasoning

PS4 is not met at the ACMG/AMP 2015 strong strength. The governing definition requires the prevalence of the variant in affected individuals to be significantly increased compared with controls, and Note 1 specifies OR/RR >5.0 with a confidence interval excluding 1.0. No paper in the reviewed literature provides affected-case and unaffected/population-control counts for the exact MSH3 NM_002439.5:c.1327G>A (p.Ala443Thr) variant, and the two relevant extracted papers do not mention this variant. gnomAD provides control-population frequency only (gnomAD v4.1 total AF 1.85893e-06; 3/1,613,828 alleles), not an affected-case frequency, so no case-control OR or 95% CI can be calculated.

Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • PMID:25394175 was selectively checked through its extracted full-text finding and direct quote; it discusses constitutional mismatch repair deficiency caused by biallelic MLH1, MSH2, MSH6, or PMS2 variants and does not mention MSH3 c.1327G>A or p.Ala443Thr.
  • PMID:26991699 was selectively checked through its extracted full-text finding and direct quote; it reports MMR-gene mutations in 93 colorectal tumor samples but does not identify this exact variant or provide variant-specific case-control data.
  • gnomAD v4.1 reports the exact variant at 3/1,613,828 alleles (AF 1.85893e-06; 0 homozygotes), which is a control-population observation without an affected-case numerator; therefore no OR or 95% CI was calculated.
Still missing
  • No exact-variant affected-case frequency and matched control frequency were available, so an OR and 95% CI could not be calculated.
Sources
PM1 ACMG_2015Not met: Cancer Hotspots found no statistically significant MSH3 A443 hotspot, and no critical-domain annotation covers residue 443. Details ▾Hide ▴
Reasoning

The variant affects MSH3 residue Ala443. No MSH3 VCEP domain table is present, so there is no authoritative approved critical-domain entry to match. Cancer Hotspots returned no statistically significant hotspot for MSH3 A443, and the reviewed evidence supplies no documented well-established critical functional domain at residue 443 or evidence of absence of benign variation within such a domain. The generic PM1 requirement is therefore not met.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • Cancer Hotspots query MSH3 A443 returned no result and reported that the variant does not lie in a statistically significant hotspot.
  • vcep_materials.json contains no MSH3 domain table or gene-specific PM1 specification.
Sources
PM5 ACMG_2015Not met: zero same-residue comparator candidates were identified for MSH3 Ala443, so no different pathogenic missense change supports PM5. Details ▾Hide ▴
Reasoning

NM_002439.5:c.1327G>A causes the missense substitution p.Ala443Thr. The reviewed comparator collection contains zero same-residue candidates, and no different missense substitution at MSH3 Ala443 is documented as pathogenic in the available evidence. Therefore the PM5 same-residue requirement is not met.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
Evidence considered
  • pm5_candidates.json reports total_candidates_seen=0 and same_residue_candidates=0 for MSH3 p.Ala443.
  • No pathogenic different missense substitution at residue Ala443 is present in the reviewed evidence.
Sources
pm5_candidates
PP3 ACMGNot met: REVEL 0.222 is below the PP3 supporting cutoff of >=0.644 for this missense variant. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_002439.5:c.1327G>A (p.Ala443Thr), so the generic missense path requires REVEL only. REVEL is 0.222, which is below the generic PP3 supporting threshold of >= 0.644; therefore PP3 is not met. SpliceAI (max delta 0.004) is not used for a missense PP3 assessment, and BayesDel is not available for generic ACMG/AMP strength calibration.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... Missense variant -> REVEL only. ... PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Local REVEL lookup for MSH3 NM_002439.5:c.1327G>A (p.Ala443Thr): score 0.222.
  • ClinGen SVI REVEL calibration threshold supplied for generic PP3 supporting evidence: >= 0.644 (Pejaver et al. 2022, PMID:36413997).
  • The missense-specific rule selects REVEL only; the available SpliceAI max delta 0.004 and BayesDel score -0.384089 were not counted for PP3.
Sources
revel
PP5 ACMG_2015Not met: ClinVar has no exact-variant expert-panel Pathogenic or Likely pathogenic classification, only single-submitter assertions. Details ▾Hide ▴
Reasoning

PP5 is not met. The exact ClinVar record for NM_002439.5:c.1327G>A (p.Ala443Thr) has no expert-panel submission; it contains one single-submitter Likely benign assertion and three single-submitter Uncertain significance assertions. The exact-variant ClinVar classification is therefore not an expert-panel Pathogenic or Likely pathogenic classification, and the literature checked for the ClinVar citation does not report this variant.

Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 1055567 exactly matches NM_002439.5(MSH3):c.1327G>A (p.Ala443Thr) and reports 0 expert-panel submissions; the submissions are one Likely benign and three Uncertain significance single-submitter assertions.
  • PMID:25394175 is the ClinVar-linked paper screened for PP5; its extracted finding states that MSH3 and the exact c.1327G>A/p.Ala443Thr variant are not mentioned.
Sources
BA1 ACMG_2015Not met: gnomAD v4.1 grpmax FAF is 6.8e-07, far below the BA1 threshold of 0.05. Details ▾Hide ▴
Reasoning

BA1 is not met. Under the generic default, the frequency threshold is >=0.05. The required filtering frequency is the gnomAD v4.1 grpmax FAF, 6.8e-07, which is far below 0.05; the highest observed population point estimate, 2.54239e-06 in European (non-Finnish) individuals, is not used to override the FAF requirement. The variant is also not supported by a high-frequency benign population signal that would warrant ending classification.

Rule
BA1: Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v4.1 reports grpmax FAF=6.8e-07 for 3/1,613,828 total alleles; the European (non-Finnish) point estimate is 2.54239e-06 from 3/1,179,990 alleles, but BA1/BS1 assessment uses grpmax FAF rather than popmax point estimate.
  • The grpmax FAF is below the generic BA1 threshold of 0.05 (5%), so the stand-alone benign criterion is not met.
Sources
BS1 ACMG_2015Not met: gnomAD v4.1 grpmax FAF is 6.8e-07 versus the generic BS1 threshold of 0.01. Details ▾Hide ▴
Reasoning

BS1 is not met. The generic default threshold is >=0.01, but the required filtering frequency is gnomAD v4.1 grpmax FAF=6.8e-07, below 0.01. This FAF is based on a population with 1,179,990 observed alleles, exceeding the 2,000-allele minimum; therefore the low FAF is not an isolate-sample artifact. The available population data do not establish an allele frequency greater than expected for the MSH3-associated disorder, and no maximum-credible-frequency calculation is needed because the observed filtering frequency is already far below the default threshold.

Rule
BS1: Allele frequency is greater than expected for the disorder.
Evidence considered
  • gnomAD v4.1 reports grpmax FAF=6.8e-07; the relevant European (non-Finnish) population has 1,179,990 observed alleles, above the 2,000-allele minimum.
  • The filtering FAF is below the generic BS1 default of 0.01, so BS1 is not met on population frequency. The European point estimate of 2.54239e-06 is not substituted for grpmax FAF.
Sources
BS2 ACMG_2015Not met: gnomAD v4.1 reports 0 homozygotes among 3 observed alleles and 1,613,828 total alleles. Details ▾Hide ▴
Reasoning

BS2 is not met. The variant is observed in gnomAD v4.1 in 3 of 1,613,828 alleles, with 0 homozygotes; gnomAD v2.1 also reports 0 homozygotes, and the non-cancer exome subset reports 0 homozygotes. Therefore, no healthy adult homozygous observation is available for this variant. The absence of homozygotes cannot satisfy the positive observation required by BS2.

Rule
BS2: Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v4.1 reports 3/1,613,828 total alleles and homozygotes=0; gnomAD v2.1 reports 1/251,196 alleles and homozygotes=0.
  • The gnomAD v2.1 non-cancer exome subset reports 1/236,662 alleles and homozygotes=0.
  • Because no homozygous observation is reported, the evidence does not meet the required healthy-adult homozygote observation for a recessive disorder.
Sources
BP6 ACMG_2015Not met: the only exact-variant Likely benign ClinVar assertion is single-submitter, with no expert-panel benign classification. Details ▾Hide ▴
Reasoning

BP6 is not met. The exact ClinVar record includes a single-submitter Likely benign assertion from Ambry Genetics, but no expert-panel Likely benign or Benign classification. The other exact-variant submissions are Uncertain significance, and no reputable-source benign report meeting the required expert-panel condition is present.

Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 1055567 exactly matches the variant and reports one single-submitter Likely benign assertion, three single-submitter Uncertain significance assertions, and zero expert-panel submissions; ordinary laboratory assertions do not satisfy the required expert-panel condition.
Sources

Not assessed · 12 · no assessment recorded

PS2 ACMG_2015Not assessed: no documented proband disease, family-history status, or confirmed maternity and paternity is available for this variant. Details ▾Hide ▴
Reasoning

No case-specific evidence documents a patient with the disease, absence of family history, or confirmed maternity and paternity for NM_002439.5:c.1327G>A. Therefore, the required evidence for PS2 cannot be assessed.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • No case-specific proband, family-history, maternity, paternity, or parental-genotype findings were provided for NM_002439.5:c.1327G>A.
Still missing
  • Documented proband phenotype and disease diagnosis
  • Family-history status
  • Parental testing confirming both maternity and paternity
  • Variant presence or absence in each parent
PS3 ACMG_2015Not assessed: no variant-specific functional assay or damaging-effect result was identified for MSH3 p.Ala443Thr. Details ▾Hide ▴
Reasoning

No variant-specific in vitro or in vivo functional assay for MSH3 NM_002439.5:c.1327G>A (p.Ala443Thr) was identified in the available evidence. OncoKB explicitly reports no variant-specific reviewed functional evidence, and the reviewed publications do not mention this variant or provide an assay result for it. Therefore, the evidence is insufficient to assess PS3 rather than supporting a damaging functional effect.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • OncoKB reports no variant-specific reviewed functional evidence for MSH3 p.Ala443Thr and labels its effect unknown.
  • Hampel et al. (PMID:25394175) does not mention MSH3 p.Ala443Thr or provide functional assay evidence for this variant.
  • The colorectal tumor sequencing study (PMID:26991699) does not explicitly mention MSH3 c.1327G>A/p.Ala443Thr and provides no variant-specific functional assay result.
Still missing
  • A validated, biologically relevant in vitro or in vivo assay testing MSH3 p.Ala443Thr, with appropriate controls and reproducible results, is needed.
Sources
PM3 ACMG_2015Not assessed: no affected-proband observation or parental/offspring phase testing establishes this variant in trans with a pathogenic variant. Details ▾Hide ▴
Reasoning

PM3 cannot be assessed because the available evidence does not report an affected proband carrying NM_002439.5:c.1327G>A with a pathogenic variant in trans, and it contains no parental or offspring testing establishing phase. The ClinVar record for this exact variant contains clinical laboratory classifications but no phase, affected-proband, or pathogenic-in-trans observation. The reviewed literature extracts do not mention this variant.

Rule
PM3: For recessive disorders, detected in trans with a pathogenic variant ... Note: This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • ClinVar variation 1055567 exactly matches NM_002439.5(MSH3):c.1327G>A (p.Ala443Thr), but the four listed submissions provide no affected-proband observation, parental/offspring phase result, or pathogenic variant reported in trans.
  • The reviewed paper extracts do not mention MSH3 c.1327G>A or p.(A443T) and provide no variant-specific allelic evidence.
Still missing
  • Affected-proband data for NM_002439.5:c.1327G>A paired with a pathogenic variant are unavailable.
  • Parental or offspring testing establishing trans phase is unavailable.
  • The pathogenicity and identity of any alleged second allele are unavailable.
Sources
PM6 ACMG_2015Not assessed: no documented assumed de novo occurrence is available, regardless of whether parental maternity or paternity was confirmed. Details ▾Hide ▴
Reasoning

No case-specific evidence documents an assumed de novo occurrence of NM_002439.5:c.1327G>A without confirmed maternity and paternity. The available records do not establish a de novo event, so PM6 cannot be assessed.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • No case-specific parental testing, de novo statement, or inheritance result was provided for NM_002439.5:c.1327G>A.
Still missing
  • Evidence that the variant is de novo or assumed de novo
  • Parental testing results and whether maternity and paternity were confirmed
PP1 ACMG_2015Not assessed: no affected relatives, matching genotypes, phenotype concordance, or informative meioses are documented for segregation analysis. Details ▾Hide ▴
Reasoning

No affected family members, genotype results, phenotype concordance, or meioses are documented for NM_002439.5:c.1327G>A. Consequently, co-segregation in a gene definitively known to cause the disease cannot be evaluated at supporting or stronger 2015 strength.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease. ... May be used as stronger evidence with increasing segregation data.
Evidence considered
  • No family segregation data for NM_002439.5:c.1327G>A were provided, including affected relatives, genotypes, phenotypes, or informative meioses.
Still missing
  • Affected relatives with a phenotype relevant to the disease
  • Variant genotypes for affected and unaffected relatives
  • Phenotype-genotype concordance
  • Number of informative meioses
PP2 ACMG_2015Not assessed: gnomAD v4.1 AF is 1.85893e-06, but gene-wide evidence for low benign missense variation and a common missense mechanism is missing. Details ▾Hide ▴
Reasoning

The variant is rare in gnomAD v4.1 (AF 1.85893e-06; 3/1,613,828 alleles), but PP2 requires gene-level evidence that MSH3 has a low rate of benign missense variation and that missense variants are a common disease mechanism. The available case evidence does not provide a comprehensive missense-spectrum analysis or establish both required gene-level conditions, so PP2 is not assessed.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • gnomAD v4.1 reports the variant at AF 1.85893e-06, 3 of 1,613,828 alleles, with no homozygotes; this is variant-level rarity and does not establish either PP2 gene-level condition.
Still missing
  • A gene-wide, validated assessment of benign missense variation in MSH3.
  • Evidence that missense variants are a common mechanism of MSH3-related disease.
Sources
PP4 ACMG_2015Not assessed: no patient phenotype or family-history details were available to evaluate high specificity for a single-gene disease. Details ▾Hide ▴
Reasoning

PP4 cannot be assessed because the case evidence supplied for this criterion does not describe the patient's phenotype, family history, or a disease-specific clinical presentation. The exact variant and gene are known, but no patient-level phenotype is available to determine whether it is highly specific for a disease with a single genetic etiology.

Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Still missing
  • Patient phenotype and family-history details are required to assess PP4.
BS3 ACMG_2015Not assessed: no validated variant-specific assay demonstrated that MSH3 p.Ala443Thr has no damaging effect on protein function or splicing. Details ▾Hide ▴
Reasoning

No variant-specific in vitro or in vivo functional assay for MSH3 NM_002439.5:c.1327G>A (p.Ala443Thr) was identified in the available evidence. The reviewed sources provide neither a validated assay demonstrating preserved protein function or splicing nor a reproducible benign functional result. Therefore, the evidence is insufficient to assess BS3 rather than supporting a no-damaging-effect conclusion.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • OncoKB reports no variant-specific reviewed functional evidence for MSH3 p.Ala443Thr; this does not establish a benign functional effect.
  • Hampel et al. (PMID:25394175) does not mention MSH3 p.Ala443Thr or provide functional assay evidence for this variant.
  • The colorectal tumor sequencing study (PMID:26991699) does not explicitly mention MSH3 c.1327G>A/p.Ala443Thr and provides no variant-specific functional assay result.
Still missing
  • A validated, biologically relevant in vitro or in vivo assay testing MSH3 p.Ala443Thr, with appropriate controls and reproducible evidence of preserved function or splicing, is needed.
Sources
BS4 ACMG_2015Not assessed: no affected relatives with documented variant-negative testing are available to demonstrate lack of segregation. Details ▾Hide ▴
Reasoning

No affected family members or their variant genotypes are documented, so lack of segregation cannot be evaluated. The available evidence also does not establish whether phenocopies or more than one pathogenic variant could explain any family phenotype.

Rule
Lack of segregation in affected members of a family. ... Caveat: The presence of phenocopies for common phenotypes (i.e. cancer, epilepsy) can mimic lack of segregation among affected individuals. Also, families may have more than one pathogenic variant contributing to an autosomal dominant disorder, fu
Evidence considered
  • No affected-relative genotype or phenotype data were provided for evaluating non-segregation of NM_002439.5:c.1327G>A.
Still missing
  • Affected relatives with reliable disease phenotyping
  • Variant testing results in affected relatives
  • Assessment for phenocopies and additional pathogenic variants
BP1 ACMG_2015Not assessed: the available registered evidence does not establish that MSH3 disease is caused primarily by truncating variants. Details ▾Hide ▴
Reasoning

The variant is a missense substitution in MSH3. The available registered evidence does not establish that MSH3-related disease is caused primarily by truncating variants, which is the gene-level premise required for BP1. A missense consequence alone cannot establish or exclude that premise, so BP1 is not assessed.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • Variant consequence is missense, NP_002430.3:p.(Ala443Thr); no registered source in this case establishes the required primarily-truncating MSH3 disease spectrum.
Still missing
  • A curated disease-variant spectrum demonstrating that truncating MSH3 variants primarily cause the relevant disease.
BP2 ACMG_2015Not assessed: the exact variant record contains no phase or second-variant data demonstrating trans occurrence in a dominant disorder or cis occurrence with a pathogenic variant. Details ▾Hide ▴
Reasoning

BP2 cannot be assessed because the available evidence does not establish that NM_002439.5:c.1327G>A is in trans with a pathogenic variant in a fully penetrant dominant disorder or in cis with a pathogenic variant. The exact-match ClinVar record contains no phase or second-variant data, and the reviewed literature extracts do not mention this variant.

Rule
BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • ClinVar variation 1055567 exactly matches NM_002439.5(MSH3):c.1327G>A (p.Ala443Thr), but the four listed submissions provide no cis/trans phase result or pathogenic second variant.
  • The reviewed paper extracts do not mention MSH3 c.1327G>A or p.(A443T) and provide no variant-specific allelic evidence.
Still missing
  • No phase-resolved result is available for a pathogenic variant paired with NM_002439.5:c.1327G>A.
  • No evidence establishes a fully penetrant dominant MSH3 disorder for the trans path.
  • The pathogenicity and identity of any alleged second allele are unavailable.
Sources
BP5 ACMG_2015Not assessed: no case evidence showed this variant alongside an alternate molecular basis for the patient's disease. Details ▾Hide ▴
Reasoning

BP5 cannot be assessed because no case-level information shows that this variant was found in a patient with an alternate molecular basis for the disease. The available ClinVar submissions and population data do not establish an alternate molecular diagnosis in a case.

Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • The exact-match ClinVar submissions contain laboratory classifications but no documented case-level alternate molecular diagnosis; therefore they cannot establish BP5.
Still missing
  • A case report or clinical record documenting an alternate molecular basis in the same affected patient is required.
Sources
Not applicable · 4· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_002439.5:c.1327G>A in MSH3 is a missense substitution predicted to produce NP_002430.3:p.(Ala443Thr). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for MSH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_002439.5:c.1327G>A in MSH3 is a missense substitution predicted to produce NP_002430.3:p.(Ala443Thr). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for MSH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_002439.5:c.1327G>A in MSH3 is a missense substitution predicted to produce NP_002430.3:p.(Ala443Thr). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for MSH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_002439.5:c.1327G>A in MSH3 is a missense substitution predicted to produce NP_002430.3:p.(Ala443Thr). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for MSH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
MSH3
Transcript
NM_002439.5
Coding (HGVS c.)
NM_002439.5:c.1327G>A
Protein (HGVS p.)
NP_002430.3:p.(Ala443Thr)
GRCh38
chr5:80679080 G>A
GRCh37
chr5:79974899 G>A
Location and type
Exon 8 · missense
ClinVar
1055567

Gene diagram

Every interpreted variant in MSH3, mapped onto the exon structure of NM_002439.5. Select a row to find it on the plot.

MSH3NM_002439.5
Fetching transcript structure from UCSC…
gnomAD v4.1 3 / 1,613,828 alleles AF 1.86e-06 · 0 homozygotes · FAF 6.8e-07
gnomAD v2.1 1 / 251,196 alleles AF 3.98e-06 · 0 homozygotes
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 1.9e-06 · 3 / 1,613,828 alleles · 0 hom · FAF 6.8e-07
European (non-Finnish)3 / 1,179,990 2.5e-06
0 alternate alleles recorded in 9 other groups: Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.

gnomAD v2.1

AF 4e-06 · 1 / 251,196 alleles · 0 hom
European (non-Finnish)1 / 113,522 8.8e-06
0 alternate alleles recorded in 7 other groups: African/African American, Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), Remaining individuals, South Asian.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 1.85893e-06; MAF= 0.00019%, 3/1613828 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 2.54239e-06; MAF= 0.00025%, 3/1179990 alleles, homozygotes = 0); grpmax FAF= 6.8e-07.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.98096e-06; MAF= 0.00040%, 1/251196 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.80887e-06; MAF= 0.00088%, 1/113522 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +136 bp
0.004
SpliceAI acceptor gainat -89 bp
0.000
SpliceAI donor lossat +271 bp
0.001
SpliceAI donor gainat -249 bp
0.000
Pangolin splice lossmagnitude shown
-0.001
Pangolin splice gain
0.001

Other predictors

REVEL
0.222
BayesDel
-0.384

How the predictions were used

BP4 SupportingACMGMet: REVEL 0.222 is below the BP4 supporting cutoff of <=0.29 for this missense variant. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_002439.5:c.1327G>A (p.Ala443Thr), so the generic missense path requires REVEL only. REVEL is 0.222, which is <= 0.29 and meets the generic BP4 supporting threshold; therefore BP4 is met at Supporting strength. SpliceAI (max delta 0.004) is not used for a missense BP4 assessment, and BayesDel is not available for generic ACMG/AMP strength calibration.

Rule
BP4: Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc) ... Missense variant -> REVEL only. ... BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Local REVEL lookup for MSH3 NM_002439.5:c.1327G>A (p.Ala443Thr): score 0.222.
  • ClinGen SVI REVEL calibration threshold supplied for generic BP4 supporting evidence: <= 0.29 (Pejaver et al. 2022, PMID:36413997).
  • The missense-specific rule selects REVEL only; the available SpliceAI max delta 0.004 and BayesDel score -0.384089 were not counted for BP4.
Sources
revel
PP3 ACMGNot met: REVEL 0.222 is below the PP3 supporting cutoff of >=0.644 for this missense variant. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, NM_002439.5:c.1327G>A (p.Ala443Thr), so the generic missense path requires REVEL only. REVEL is 0.222, which is below the generic PP3 supporting threshold of >= 0.644; therefore PP3 is not met. SpliceAI (max delta 0.004) is not used for a missense PP3 assessment, and BayesDel is not available for generic ACMG/AMP strength calibration.

Rule
PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.). ... Missense variant -> REVEL only. ... PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Local REVEL lookup for MSH3 NM_002439.5:c.1327G>A (p.Ala443Thr): score 0.222.
  • ClinGen SVI REVEL calibration threshold supplied for generic PP3 supporting evidence: >= 0.644 (Pejaver et al. 2022, PMID:36413997).
  • The missense-specific rule selects REVEL only; the available SpliceAI max delta 0.004 and BayesDel score -0.384089 were not counted for PP3.
Sources
revel
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_002439.5:c.1327G>A in MSH3 is a missense substitution predicted to produce NP_002430.3:p.(Ala443Thr). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for MSH3, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.222. BayesDel score = -0.384089.

1 paper record listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
    Hampel H et al. · 2015
    The paper does not mention MSH3 or the specific c.1327G>A / p.(A443T) variant. It discusses constitutional mismatch repair deficiency as a recessive condition caused by biallelic mutations in MLH1, MSH2, MSH6, and PMS2, without variant-specific functional evidence for this MSH3 substitution.
    Does not name this variant
    PMID 25394175 ↗
    Quoted passage
    Constitutional mismatch repair deficiency is a recessive condition caused by biallelic mutations in the mismatch repair genes (MLH1, MSH2 (including methylation due to an EPCAM deletion), MSH6, and PMS2) and is characterized by a high risk of developing cancers during childhood, including Lynch syndrome (LS)–associated cancers, hematologic malignancies, and embryonic tumors.

    Page 77, section "Constitutional mismatch repair deficiency"

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 1.85893e-06; MAF= 0.00019%, 3/1613828 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 2.54239e-06; MAF= 0.00025%, 3/1179990 alleles, homozygotes = 0); grpmax FAF= 6.8e-07.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 3.98096e-06; MAF= 0.00040%, 1/251196 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.80887e-06; MAF= 0.00088%, 1/113522 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Uncertain significance (3 clinical laboratories) and as Likely benign (1 clinical laboratory). (ClinVarID = 1055567)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.222. BayesDel score = -0.384089.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. MSH3, a DNA mismatch repair protein, is frequently mutated in colorectal cancers.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.